In conclusion, we demonstrate the synergistic effect of the combination therapy with AKT (AZD5363) and mTOR (AZD2014 and BEZ235) inhibitors against bladder cancer cells with PI3KCA and mTOR mutations. The gene discussed is AKT1; the disease is urinary bladder carcinoma.